JPRN-UMIN000018711已完成未知
The protective effect of canagliflozin on renal function in obese patients with T2DM - The protective effect of canagliflozin on renal function in obese patients with T2DM
Division of Nephrology, Nippon Medical School0 个研究点目标入组 20 人开始时间: 2015年9月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) HbA1C >9.0% 2) Allergy to canagliflozin 3) Severe ketoacidosis or diabetic coma 4) severe infection, operation, and trauma 5)T1DM 6) Moderate to severe renal disfuction (eGFR <45ml/min/1.73m2) 7) Heart failure (NYHA IV) 8) possibility of hypoglycemia by canagliflozine such as hypopituitarism, adrenal insuficiency, excessive exercise, malnutition, excess alcohol intake. 9) Dehydration 10) severe liver disfunction (AST and ALT > 5 x normal range of the hospital) 11) Age more than 70 years 12) Age less than 20 years 13) Pregnant or breastfeeding mother 14) patients who was regarded as uneligible by the doctor
研究者
相似试验
招募中
不适用
FAGOTTO studyDiabetes Mellitus, Type 2JPRN-jRCTs041200069Maruyama Shoichi110
已完成
1 期
A Study of the Effects of Canagliflozin on Plasma Volume in Patients With Type 2 Diabetes MellitusPlasma VolumeDiabetes Mellitus, Type 2NCT01483781Janssen Research & Development, LLC36
招募中
4 期
Effect of empagliflozin on renal events in non-diabetic chronic kidney disease patientsChronic kidney disease.Chronic kidney disease (CKD)IRCT20211104052965N1Shahid Beheshti University of Medical Sciences458
已完成
3 期
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic NephropathyDiabetic NephropathyDiabetes Mellitus, Type 2NCT02065791Janssen Research & Development, LLC4,401
已完成
不适用
Study of the beneficial effect of Canagliflozin on nocturnal home BP in Japanese T2DM patients(SHIFT-J STUDY)Type 2 diabetes mellitus patients with hypertensionJPRN-UMIN000023487Jichi Medical University School of Medicine100